bioRxivImmunology
Autoantibody subclass predominance is not driven by aberrant class switching or impaired B cell development
L. M. Paardekooper, Y. E. Fillie-Grijpma, A. J. van der Sluijs-Gelling, M. Zlei, R. van Doorn, M. H. Vermeer, M. Paunovic, M. J. Titulaer, S. M. van der Maarel, J. J. M. van Dongen, J. J. Verschuuren, M. G. Huijbers
Abstract
A subset of autoimmune diseases is characterized by predominant pathogenic IgG4 autoantibodies (IgG4-AIDs). Why IgG4 predominates in these disorders is unknown. We hypothesized that dysregulated B cell maturation or aberrant class switching causes overrepresentation of IgG4+ B cells and plasma cells. Therefore, we compared the B cell compartment of patients with muscle-specific kinase (MuSK) myasthenia gravis (MG), pemphigus, leucine-rich glioma inactivated (LGI1) encephalitis and contactin-associated protein-like 2 (CASPR2) encephalitis (four IgG4-AIDs) to patients with acetylcholine receptor (AChR) MG, Lambert-Eaton myasthenic syndrome (LEMS) (two IgG1-3-AIDs) and age-matched healthy donors, using flow cytometry. B cell subset relative abundance at all maturation stages was normal, except for a, possibly treatment-related, reduction in immature and naive CD5+ cells in IgG4-AIDs. IgG4+ B cell and plasma cell fractions were normal in IgG4-AID patients, however they had an (sub)class-independent 8-fold increase in circulating mature CD20-CD138+ plasma cells. No autoreactivity was found in this subset after sorting. In conclusion, patients with IgG4-AID do not show increased numbers of IgG4-expressing cells. These results argue against aberrant B cell development in these patients and rather suggest the autoantibody subclass predominance to be antigen-driven. The similarities between B cell subset numbers among these patients suggest that these IgG4-AIDs, despite displaying variable clinical phenotypes, share a similar underlying immune profile. Graphical abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=119 SRC="FIGDIR/small/546522v1_ufig1.gif" ALT="Figure 1"> View larger version (26K): org.highwire.dtl.DTLVardef@1444429org.highwire.dtl.DTLVardef@d70867org.highwire.dtl.DTLVardef@168a7c0org.highwire.dtl.DTLVardef@1dd4483_HPS_FORMAT_FIGEXP M_FIG C_FIG
- organism: human
- assay: flow cytometry
- research focus: cell type annotation
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- IgG4 antibody repertoire diversity is stable over several years in health and autoimmune disease
Linus Wollenweber, Laurent M. Paardekooper, … Maartje G. M. Huijbers·bioRxiv·Oct 6, 2026
- Distinct transcriptional programs define human IgG4+ memory B cells
Laurent M. Paardekooper, Jessica M van Bokkum, … Maartje G. M. Huijbers·bioRxiv·Jun 9, 2026
- Isolation and characterization of rare circulating autoantibody-producing cells from patients with muscle-specific kinase myasthenia gravis
K. Takata, P. Stathopoulos, … K. C. O'Connor·bioRxiv·Dec 13, 2018
- Elevated N-glycosylation of immunoglobulin G variable regions in myasthenia gravis highlights a commonality across autoantibody-associated diseases
C. Mandel-Brehm, M. L. Fichtner, … K. C. OConnor·bioRxiv·Mar 6, 2021
- Functional monovalency amplifies the pathogenicity of anti-MuSK IgG4 in myasthenia gravis
D. L. E. Vergoossen, J. J. Plomp, … M. G. Huijbers·bioRxiv·Sep 24, 2020
- Self-antigen driven affinity maturation is required for pathogenic monovalent IgG4 autoantibody development
M. L. Fichtner, C. Vieni, … K. C. O'Connor·bioRxiv·Mar 14, 2020